Resource Summary Report

Generated by RRID on May 15, 2025

Dartmouth Hitchcock Medical Center Geisel School of Medicine Pathology Shared Resource Core Facility

RRID:SCR_023479
Type: Tool

Proper Citation

Dartmouth Hitchcock Medical Center Geisel School of Medicine Pathology Shared Resource Core Facility (RRID:SCR_023479)

Resource Information

URL: https://cancer.dartmouth.edu/scientists-researchers/pathology-shared-resource

Proper Citation: Dartmouth Hitchcock Medical Center Geisel School of Medicine Pathology Shared Resource Core Facility (RRID:SCR_023479)

Description: Facilitates project planning, clinical validation and implementation of novel translational technology and research in fields of molecular diagnostics, molecular therapeutics, pharmacogenomics, quantitative morphologic image analysis and immunohistochemistry in CLIA-certified, CAP-accredited laboratory ensuring optimal clinical quality assurance.

Synonyms: DH Pathology Shared Resource, Geisel School of Medicine at Dartmouth DH Pathology Shared Resource

Resource Type: service resource, core facility, access service resource

Keywords: USEDit, ABRF, project planning, clinical validation and implementation of novel translational technology, molecular diagnostics, molecular therapeutics, pharmacogenomics, quantitative morphologic image analysis, immunohistochemistry

Funding:

Resource Name: Dartmouth Hitchcock Medical Center Geisel School of Medicine Pathology Shared Resource Core Facility

Resource ID: SCR_023479

Alternate IDs: ABRF_1731

Alternate URLs: https://coremarketplace.org/?FacilityID=1731&citation=1

Record Creation Time: 20230419T050215+0000

Record Last Update: 20250514T061956+0000

Ratings and Alerts

No rating or validation information has been found for Dartmouth Hitchcock Medical Center Geisel School of Medicine Pathology Shared Resource Core Facility.

No alerts have been found for Dartmouth Hitchcock Medical Center Geisel School of Medicine Pathology Shared Resource Core Facility.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID.

Bentz JL, et al. (2024) High-Risk HPV Screening Initiative in Kosovo-A Way to Optimize HPV Vaccination for Cervical Cancer. Diseases (Basel, Switzerland), 12(8).

Jones VM, et al. (2024) Angiomyolipomatous Lesions of the Nasal Cavity (Sinonasal Angioleiomyoma with Adipocytic Differentiation): A Multi-Institutional Immunohistochemical and Molecular Study. Research square.

Bagheri M, et al. (2024) Alteration of DNA methyltransferases by eribulin elicits broad DNA methylation changes with potential therapeutic implications for triple-negative breast cancer. Epigenomics, 16(5), 293.

Tau S, et al. (2024) Endocrine persistence in ER+ breast cancer is accompanied by metabolic vulnerability in oxidative phosphorylation. bioRxiv : the preprint server for biology.

Schwartz GN, et al. (2023) Alternating 17?-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(15), 2767.

Traphagen NA, et al. (2023) Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer. Clinical cancer research : an official

journal of the American Association for Cancer Research, 29(18), 3717.